« Roslin Cell Sciences relocates to larger premises at Roslin BioCentre | Main | Cell Therapy Catapult & Roslin Cells to create clinical grade stem cells to accelerate research into new treatments »

Roslin Cells announces the creation of two commercially focused subsidiaries: Roslin Cell Therapies and Roslin Cell Sciences  

Edinburgh, Scotland, 11th January 2016

Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations.  Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trials.  Roslin Cell Sciences will focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.  

Roslin Cell Therapies 

Roslin Cell Therapies builds on the wealth of expertise and industry recognition developed by Roslin Cells in the process development and manufacture of Cell Therapies and Advanced Therapy Medicinal Products (ATMPs).  Based at Edinburgh BioQuarter, where it operates purpose built clean room facilities, the company will continue to provide contract manufacturing services for clinical trial supply. 

Roslin Cell Sciences

Roslin Cell Sciences will focus on further development of Roslin Cells’ expertise in the creation of induced Pluripotent Stem Cells (iPSCs) for commercial and academic drug research. There is an increasing appreciation that iPSCs offer a wholly new means of evaluating new drugs and their suitability for particular patients. With facilities in both Edinburgh and Cambridge, UK, the company is capable of creating large numbers of iPS cell lines from cohorts of donors. Creating cell lines in this way will enable researchers to understand better how drug performance varies between individuals due to their genetic variation.  


Aidan Courtney, Chief Executive Officer stated “Since we founded the company in 2006, it has developed two distinct businesses both operating in rapidly developing markets – the manufacture of cell therapies and the use of iPSCs for research.  By creating two separate commercial entities, we will be best placed to maximise the growth and success of both.” 

Press Contacts

For more information, please contact:

Roslin Cell Therapies

Dr Daria Olijnyk-Dallis,  Business Development Executive

Tel: +44 (0)131 658 5180

Mobile:  +44 (0)7867494071

Email: daria.olijnyk-dallis@roslincells.com

Web : www.roslincells.com/roslincelltherapies 

Roslin Cell Sciences

Kevin Bruce,  Head of Commercial

Tel: +44 (0)131 440 6543

Mobile: +44 (0)7825 393 287

Email: kevin.bruce@roslincs.com

Web: www.roslincells.com/roslincellsciences